Department of Medical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, Leiden, The Netherlands.
Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
Breast Cancer Res Treat. 2019 Nov;178(1):141-149. doi: 10.1007/s10549-019-05356-z. Epub 2019 Jul 19.
The number of older patients with breast cancer is rapidly increasing. A previous study showed that between 1990 and 2005, the survival of older patients with breast cancer did not improve in contrast to younger patients. In recent years, scientific evidence in the older age group has increased and specific guidelines for older women with breast cancer have been developed. The aim of this study was to assess changes in survival outcomes of older patients with breast cancer.
All patients with breast cancer between 2000 and 2017 were included from the Netherlands cancer registry. We assessed changes in treatments using logistic regression. We calculated changes in relative survival as proxy for breast cancer mortality, stratified by age and stage.
We included 239,992 patients. Relative survival improved for patients < 65 for all stages. In patients aged 65-75 years, relative survival did not improve in stage I-II but did improve in stage III breast cancer (RER 0.98, 95% CI 0.96-1.00, p = 0.046). Concurrently, prescription of systemic treatments increased. In patients > 75, relative survival did not improve in patients with stage I/II or stage III disease, nor did treatment strategies change.
This study shows that relative survival of patients aged 65-75 years with advanced breast cancer has improved, and concurrently, prescription of systemic treatment increased. To improve survival of patients > 75 as well, future studies should focus on individualizing treatments based on concomitant comorbidity, geriatric parameters and the risk of competing mortality and toxicity of treatments.
患有乳腺癌的老年患者人数正在迅速增加。先前的一项研究表明,1990 年至 2005 年间,与年轻患者相比,老年乳腺癌患者的生存率并未提高。近年来,老年患者群体中的科学证据不断增加,并且已经为老年乳腺癌女性制定了具体的指南。本研究旨在评估老年乳腺癌患者生存率的变化。
从荷兰癌症登记处纳入了所有 2000 年至 2017 年期间患有乳腺癌的患者。我们使用逻辑回归评估了治疗方法的变化。我们通过年龄和分期分层,计算了作为乳腺癌死亡率替代指标的相对生存率的变化。
我们纳入了 239992 名患者。所有分期的<65 岁患者的相对生存率均有所提高。在 65-75 岁的患者中,I-II 期的相对生存率没有提高,但 III 期乳腺癌的相对生存率有所提高(RER 0.98,95%CI 0.96-1.00,p=0.046)。同时,系统治疗的处方也增加了。在>75 岁的患者中,I/II 期或 III 期疾病患者的相对生存率没有提高,治疗策略也没有改变。
本研究表明,65-75 岁患有晚期乳腺癌的患者的相对生存率有所提高,同时系统治疗的处方也有所增加。为了进一步提高>75 岁患者的生存率,未来的研究应该关注根据合并症、老年参数以及治疗的竞争死亡率和毒性风险来个体化治疗。